22.7 7 8.4 mg/ml, 112.27 31.0 mg/dl and 93.6 75.5, respectively. After one month of treatment with EPA in group A, EPA/AA ratio was significantly increased (0.30 7 0.15 vs. 0.95 70.45, p o0.0001) and DHL-A significantly decreased (22.7 77.4 vs. 15.7 7 6.8, p¼ 0.0003), but DHA/AA ratio, serum non HDL-C and phosphate levels did not change. EPA/AA ratio was significantly higher and DHL-A lower in group A compared with group B after one month of the start of study. Conclusions: Medication of EPA for one month increases EPA/AA ratio, and decreases DHL-A level without the change of serum phosphate level in HD patients with low EPA/AA ratio. . We determined total 25(OH)D using the LIASON s 25 OH Vitamin D kit (DiaSorin Inc., Stillwater MN, USA). We evaluated VF with a computerized analysis of scanned L-L vertebral X-rays (T4 to L5). Reduction of 4 20% of vertebral body height was considered a VF, while reductions between 15% and 20% were considered borderline fractures (BF). Fracture severity was estimated as mild, moderate or severe (reduction: 20-25%, 25-40% or 440%, respectively). VC assessments were also centralized. Witteman's method (Lancet, 1994) was used for blinded assessments in duplicate. VC were quantified by measuring the length of calcific deposits along the anterior and posterior wall of the aorta (mild 0.1-5 cm, moderate 5.1-10 cm and severe 410 cm). We also evaluated the presence or absence of calcifications of the iliac arteries in the same radiograph (mild 0.1-3 cm, moderate 3.1-5 cm and severe 45cm). Any differences in VC were resolved by consensus. Follow up was 2.770.5 years.
Bone markers were: Ca 9.1570.68 mg/dl, P 4.87 1.28 mg/dl, median ALP 83 U/L and median PTH 244 pg/ml. We found a median 25(OH)D level of 28.9 ng/ml. Nine ( 2.3%) patients had vitamin D deficiency (o10 ng/ml), 198 (51.2%) patients had vitamin D insufficiency (between 10-29.9 ng/ml) and 180 (46.5%) patients had normal levels ( 430 ng/ml). We found that 55% of patients had VF and 30.9% of patients had BF. Prevalence of VC was 80.6% (mild 20.1%, moderate 30.8%, severe 29.7%) in the aorta and 55,1% in the iliac arteries. Males had more VF than Females (60% versus 48%, P¼0.019). No associations were found between VF and biochemical parameters including calcifediol levels (p¼0.662), while we found an association between low calcifediol levels and a higher prevalence of severe aortic calcifications (36.8 vs 28.2, p¼0.0044). Furthermore, we found a OR 1.85 (1.04-3.29 CI, p¼ 0.0367) for Aortic Calcification in patients with calcifediol levels lower than the median value of 29 ng/ml. During follow-up (2.770.5 years) mortality was of 19.9%. No association was found between mortality and calcifediol levels (p¼0.5394). In conclusion, despite good control of bone and mineral metabolism parameters, hemodialysis patients showed high prevalence of VF and VC. Our study suggests that high calcifediol levels could be protective against progression of severe aortic calcification Recently revealed high prevalence of Chronic Kidney Disease (CKD) raises concerns all over the world; evidence based strategies to delay progression were set up. Dietary approach is largely mentioned, but strong evidence is lacking.
The reduced dietary protein intake has been reported for more than a century to improve uremic symptoms and even to postpone the initiation of renal replacement therapy (RRT); however, the nutritional intervention in uremia is still under debate.
Different dietary protein regimens have been proposed for the CKD patients: (1) conventional low protein diet (LPD), with 0.6 g/kg per day; (2) very low protein diet (0.3 g/kg per day) supplemented with essential amino acids or (3) very low protein diet (0.3 g/kg per day) supplemented with an isomolar mixture of essential amino acids and nitrogen-free ketoanalogues (SVLPD).
Available data support SVLPD to be effective in ameliorating nitrogen waste products retention, acid-base and calcium-phosphorus metabolism disturbances and insulin-resistance and in delaying the RRT initiation, with no deleterious effect on the nutritional status in CKD patients.More recent studies report that SVLPD could also slow down the rate of decline in renal function, preserving the nutritional status and associating better outcome after the start of RRT.
The possible delay of RRT initiation through nutrition could have major impact on patients' quality of life. On the other hand, postponing RRT could have also a serious economic impact, particularly important in countries where the dialysis facilities still do not meet the needs. The nutritional intervention, particularly the SVLPD could be a new link in the RRT integrated care model.
However, a careful selection of motivated patients who could benefit from such a diet, close nutritional monitoring and dietary counseling are highly required. 
